<?xml version="1.0" encoding="UTF-8"?>
<p>Phase I clinical trials have been published to assess 2 DNA vaccines encoding the pre-membrane and the envelope glycoprotein of the NY99 strain of WNV, in 2007 and 2011 (Martin et al., 
 <xref rid="B134" ref-type="bibr">2007</xref>; Ledgerwood et al., 
 <xref rid="B118" ref-type="bibr">2011</xref>). Both studies demonstrated safety and efficacy in inducing neutralizing antibodies in individuals who completed 2 or 3 doses of vaccination.
</p>
